samedan logo
 
 
spacer
home > ebr > spring 2003 > utility, inventiveness and patenting dna
PUBLICATIONS
European BioPharmaceutical Review

Utility, Inventiveness and Patenting DNA

In July 2002 a group of leading scientists and lawyers looked in detail at the sometimes vexed question of patents that relate to claims involving DNA and genetic technology in general. The Nuffield Council on Bioethics comprehensively reviewed the interaction of ethical issues, with both the law of patents and its practical impact upon research and development, in the discussion paper The Ethics of Patenting DNA (1).

Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Brian Cain, Solicitor with Richards Butler

Brian Cain is a solicitor currently practising with Richards Butler. Brian is the author of Legal Aspects of Gene Technology, a new book published by Sweet & Maxwell dealing with issues ranging from potential liabilities arising out of the release or marketing of GM products to protecting the intellectual property in GM technology.

He holds a Law degree from Bristol University and a degree in Biological Sciences from the University of London.

spacer
Brian Cain
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

Clinical Trials in CNS

25-26 November 2008, Copthorne Tara Hotel, London, UK

SMi present their 7th annual conference… Clinical Trials in CNS 25th to 26th November 2008, Copthorne Tara Hotel, London, UK
More info >>

 
News and Press Releases

Azopharma Product Development Group, Inc

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement